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Abstract: Hypoxia triggers production of several cytoprotective proteins. Hypoxia-inducible factor 1alpha (HIF
-1a) is a powerful stimulator of transcription of many genes, including erythropoietin (EPO) in hypoxia-affected 
cells. Recent data have also implicated signaling by EPO receptor (EPOR) as a new factor influencing tumor 
progression. The aim of the study was to detect by immunohistochemistry the presence of HIF-1a, EPO and 
EPOR in colorectal cancer (CRC) in reference to clinicopathological variables. We found the presence of the 
studied proteins in specimens of all 125 CRC patients which is suggestive of the occurrence of hypoxia in colo-
rectal cancer tissues. The expression of HIF-1a correlated significantly with the presence of EPO and EPOR in 
all samples (P < 0.001, r = 0.549 and P < 0.001, r = 0.536, respectively). Significant correlations (from P < 0.024 
to P < 0.001) were found in the analyses of CRC subgroups such as histopathological type tumor, tumor grade, 
tumor stage and patients with lymph nodes metastases. The same high significant correlations (P < 0.001) were 
observed in group of sex, age and tumor location. However, the values of the correlation coefficients (r) which 
usually ranged from 0.5 to 0.6 suggest the existence of independent or concurrent mechanism stimulating gene-
ration of these proteins in colorectal cancer. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 320–325)
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Introduction
HIF-1a (hypoxia-inducible factor 1alpha) is a po-
werful stimulator of transcription of many genes, 
including GLUT-1, p53, p21, blc-2, VEGF and ery-
thropoietin (EPO) [1–3]. Through the expression of 
these effector genes, HIF-1a allows the cell to survive 
during hypoxia by stimulating angiogenesis and, in 
a further perspective, ensures better conditions for 
oxygen supply. Most probably, the mechanism is also 
activated in tumor progression and can be associated 
with the so called “normobaric oxygen paradox”. This 
is a dual mechanism by which oxygen regulates the 
expression of the HIF-1a [4]. 
Erythropoietin is the primary humoral regulator of 
erythropoiesis, and the reduction in partial pressure of 
oxygen (hypoxia) in the kidney is by far the strongest 
factor stimulating its synthesis. It was also demonstra-
ted that EPO can be produced by the same erythrocyte 
progenitor cells, which can be related to the auto-
crine and/or paracrine mechanism of erythropoiesis 
regulation [5, 6]. EPO and its receptor, EPOR, have 
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recently been found to be expressed on several normal 
non-hematopoietic cells as well as in cancer tissues. 
Specifically, high expression of EPOR has been found 
on the surface of endothelial cells and various solid 
tumors [7, 8]. EPO production is stimulated by HIF-1a 
in response to hypoxia which is a common phenome-
non within a neoplastic tumor, usually associated with 
resistance to treatment, higher tumor aggressiveness 
and bad prognosis. EPO and HIF-1a were intensively 
co-expressed in cervical dysplasias and invasive cervi-
cal cancers [9]. EPO seems to play a crucial role in the 
process of neoangiogenesis, promotion of survival of 
hypoxic cancer cells and tumor growth. Recent data 
have also implicated EPO/EPOR signaling as a new 
factor influencing tumor progression [10, 11]
There are very few reports on the relations be-
tween HIF-1, EPO and EPOR despite the fact that 
these factors are induced at a common signaling pa-
thway of HIF-1 transcriptional action in cases of tissue 
oxygen deficiency. We previously indicated that EPO 
expression determined by immunohistochemistry 
(IHC) highly correlated with the EPOR expression 
in colorectal cancer (CRC) [8] and described in detail 
the changes observed in the expression and location 
of HIF-1a in CRC tissue [12]. The objective of the 
current immunohistochemical study was to assess 
the correlations between expression of HIF-1a, EPO 
and EPOR in relation to pTN staging of CRC, its 
histological type, histological differentiation grade 
(G), location, as well as age and sex of patients. To 
our knowledge, this is the first report to present the 
above correlations in colorectal cancer. 
Material and methods
Our study included tissue samples of surgically removed 
colorectal cancers from 125 patients. Patients’ characteristics 
have been shown in Table 1. No individual was treated by 
either radiotherapy or chemotherapy before tumor resection 
and no one was given rHuEpo before sampling of cancer 
tissues. Each neoplastic tumor was cut in parallel to the 
longest axis to obtain at least one complete cross-section 
2–3 mm thick. It was then divided into small blocks of 1–1.5 
cm in diameter. In every case we obtained 4–8 segments of 
tumor tissue.
Tumor samples were collected immediately after tumor 
removal, fixed in 10% buffered formaldehyde solution for 
48 h and then embedded in paraffin blocks at 56°C. Accor-
ding to standard procedures, 3–5 μm thick slides were cut 
and stained with hematoxylin and eosin (HE). After the 
diagnosis of colorectal cancer was confirmed, pathological 
features were determined as AJCC/UICC TNM stage 
(American Joint Committee on Cancer/International Union 
Against Cancer Tumor Node Metastasis), histological tumor 
type (HP) and grade of histological differentiation (G). 
Due to a relatively scant number of pT1 cases we included 
pT1 and pT2 cancers into one group that corresponded 
with stage A of Dukes system. Also pT3 and pT4 cancers 
comprised a separate group which belonged to stage B and 
C of Dukes classification. This division was justified by 
expected differences in the prognosis of patients at stage 
A as compared with those at B and C stages. Moreover, 
the tumors were also divided into two histopathological 
types: non mucinous adenocarcinomas and mucinous 
adenocarcinomas, in which mucin secreting component 
made up more than 50% of all microscopically examined 
cancer fields.
Immunohistochemical methods. Immunohistochemistry 
was used to investigate colorectal cancer specimens and 
staining procedures involved antibodies against HIF-1alpha 
(sc-10790, Santa Cruz Biotechnology, USA; sc-10790), EPO 
(sc-7956, Santa Cruz Biotechnology, USA; 1:200 dilution) 
and EPOR (sc-695, Santa Cruz Biotechnology, USA; 1:400 
dilution). In order to visualize the antigen-antibody reaction, 
EnVision (Dako, Glostrup, Denmark) method was applied, 
using diaminobenzidine (DAB) as a chromogen. Slides were 
counterstained with hematoxylin. Positive controls were 
HIF-1a, EPO and EPOR immunoreactive breast cancer 
tissues [13]. Negative controls were prepared with omission 
of primary antibodies.
Immunoreactivities were assessed by two independent 
pathologists in 10 high power fields of each tumor in light 
microscopy and the mean rate of tumor immunoreactive 
(positive) cells was counted. The expression grade of the 
proteins studied was classified with the following scale: 
0 (negative cases), less than 10% of positive cancer cells; 
1+, 10–50% of positive cancer cells; 2+, over 50% of po-
sitive cells. 
Statistical analysis. Spearman rank correlation test was 
applied to evaluate the relationships of HIF-1alpha with 
EPO and EPOR among different groups of patients with 
a level of statistical significance at P < 0.05.
Results
Patterns of immunoreactivity of the studied proteins
The staining for HIF-1a was found mainly in the 
cytoplasm of cancer cells in a granular or/and diffuse 
pattern. Sometimes the protein accumulated close 
to the nuclear envelope, and only occasionally and 
discretely appeared in the nuclei of CRC cells (Figure 
1A and 1B).
EPO was present mainly in the cytoplasm of the 
CRC cells in the form of large granules. Its expres-
sion was enhanced in the vicinity of the cell nucleus 
in tumors with high EPO expression (Figure 1C and 
1D). The immunoexpression of EPOR was located 
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mainly within cell membranes, although in most ca-
ses also granular cytoplasmic reaction was observed 
(Figure 1E and 1F). In some of the analyzed cases, 
a weak diffuse cytoplasmic reaction was found, but 
the staining was considered negative and not taken 
into account because of the possibility of nonspecific 
immunohistochemical reactivity [8].
The expression of HIF-1a, EPO and EPOR in 
CRC in relation to clinicopathological variables
The immunoreactivity of HIF1a was statistically 
highly correlated with the expression of EPO and 
EPOR in the all of examined groups (Table 1). The 
statistical analysis of the respective subgroups sho-
wed the correlation (r) between HIF-1a and EPO 
expression to range from 0.475 to 0.678, and in the 
case of HIF-1a and EPOR the values were in the 
range of 0.426–0.845. At the same time, we found 
a very high statistical significance (P), usually at the 
level of P < 0.001 (Table 1). Only in the pT1+pT2 
and adenocarcinoma mucinosum (ca muc) groups, 
statistically significant relationship between HIF-1a 
and EPO expression was found at the level of 
P < 0.015 and < 0.024, respectively. It should be em-
phasized that these groups included a relatively small 
number of cancers, which could affect the statistical 
analysis (Table 1). 
Figure 1. Patterns of cellular distribution of HIF-1a, EPO and EPOR as revealed by immunohistochemistry. A and B. 
Coarsely granularly distributed immunoreactivity of HIF-1a (alpha) in cytoplasm of colorectal cancer cells (magnifica-
tions: A, × 80; B, × 200). C and D. Strong mixed cytoplasmic and membranous deposition of EPO in colorectal cancer 
cells. Some cells show enhanced accumulation of EPO in perinuclear area (C, × 200; D, × 400). E and F. Membranous and 
partly perinuclear staining of bead-like coarse granular pattern for EPOR in colorectal cancer cells (E, × 100; F, × 400)
A B
C D
E F
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Table 1. Comparison of the expression of HIF–1a with the expression of EPO and EPOR in various groups of colorectal 
cancer. Spearman’s correlation test
Groups of 
patients
HIF-1a — EPO HIF-1a — EPOR
P r P r
All patients
n = 125
 < 0.001 0.549  < 0.001 0.536
N pN (–)
n = 60
 < 0.001 0.499  < 0.001 0.509
pN ( + )
n = 65
 < 0.001 0.587  < 0.001 0.544
T pT1 + 2
n = 12
0.015 0.678 0.001 0.845
pT3 + 4
n = 113
 < 0.001 0.543  < 0.001 0.511
G G2
n = 87
 < 0.001 0.488  < 0.001 0.426
G3
n = 38
0.003 0.475 0.001 0.521
HP–type Adenoca
n = 107
 < 0.001 0.542 < 0.001 0.491
Ca muc
n = 18
0.024 0.529 0.005 0.645
Sex male
n = 64
 < 0.001 0.518  < 0.001 0.516
female
n = 61
 < 0.001 0.582  < 0.001 0.566
Age ≤ 60
n = 43
 < 0.001 0.643  < 0.001 0.612
> 60
n = 82
 < 0.001 0.497  < 0.001 0.493
Location rectum
n = 57
 < 0.001 0.554  < 0.001 0.532
colon
n = 68
 < 0.001 0.552  < 0.001 0.537
HP-type — Histopathologic type, pT — depth of intramural growth, N — lymph node involvement, G — grading of cell differentiation; Adenoca 
— adenocarcinoma; Ca muc — adenocarcinoma 
Discussion
HIF-1 is heterodimeric transcriptional factor that 
consists of two subunits: alpha(a) and beta(b). HIF-1a 
undergoes rapid degradation in normoxic conditions, 
so that proper transcriptional activity of the factor may 
take place in conditions of oxygen deficiency [14, 15]. 
The HIF-1a-depending gene regulation is responsible 
for many different genetic expressions including EPO. 
Thus, high correlation can be expected between the 
expression of HIF-1a and EPO in oxygen-deficient 
neoplastic tumors. We found a statistically significant 
correlation between HIF-1a and EPO in all study 
subgroups. However, the values of correlation coeffi-
cients (r) varied among the respective anatomo-clini-
cal subgroups and ranged between 0.5 and 0.6. These 
values of correlation coefficients (r) are relatively low 
for the theoretically very close relationships between 
the expressions of HIF-1a and EPO. It should be 
emphasized that also the correlation of EPO and 
EPOR immunoexpression in colorectal cancers was 
at the same level (r = 0.547; P < 0.00001), which was 
presented in our earlier report [8]. However in the 
previous paper we had not examined correlations be-
tween EPO and EPOR in different anatomo-clinical 
subgroups of colorectal cancer patients.
We think that the fact that HIF-1a was localized 
mainly in the cytoplasm is important for proper inter-
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pretation of our findings. The most expected location 
of immunohistochemical reaction would be a cell 
nucleus, which could suggest transcription activity 
of this factor, however, Yoshimura H et al. observed 
HIF-1a expression in the cytoplasm and nucleus of 
the colorectal cancers cells [16]. The results reported 
by many authors indicate various location of HIF-1a 
in the cell. Low-differentiated human pancreatic en-
docrine tumors (PET) show reaction for HIF-1a in 
the cell nucleus, whereas more differentiated tumors 
are characterized by cytoplasmic reaction for HIF-1a 
[17]. Similarly, Pansare et al. [18] and Giatromanolaki 
et al. [19] using a different types of HIF-1a antibodies 
have shown that endometrial cancers exhibit nuclear 
and cytoplasmic location of HIF-1a. 
Regarding some discrepancies in the reactivity of 
anti-EPOR C-20 antibody, it should be noted that 
Brown et al. [20] demonstrated that C20 antibody 
can be useful for immunohistochemical evaluation of 
EPOR. However, background staining that results from 
cross-reacting with HSP70, which is a heat shock protein 
and competes with EPOR in biding with C-20 antibody, 
seems to be a drawback of this antibody. In our study 
cytoplasm and cell membranes of colorectal cancer cells 
were stained with C-20 in granular fashion, similarly 
as described by Brown et al. [20]. The usefulness of 
C-20 antibody to detect EPOR has been confirmed in 
some recent reports [21, 22 ]. We have to remember 
too, that cancer cells can harbor numerous mutations, 
which might be responsible for cytoplasmic storage of 
some membranous proteins as in case of connexin 26 
in colorectal cancerogenesis [23]. It has been shown 
that hypoxia limits maturation of cancer cells [24]. The 
expression of HIF-1a can overcome these unfavorable 
for tumor growth effects of hypoxia via the activation of 
gene transcription and increased histological differen-
tiation of cancer despite oxygen deficiency [25]. 
The co-expression of HIF-1a, EPO and EPOR 
was also noticed in non-small cell lung cancer, thus 
implicating possible significance of HIF-1a in the 
induction of EPO and EPOR expression in pulmo-
nary tumors [26]. Hypoxia-induced expression of 
EPO was distributed in a similar fashion to HIF-1a 
in the vicinity of necrotic foci in endometrial can-
cer [27]. In our study, there was similar location 
of HIF-1a  and EPO staining in colorectal cancer 
tissues. Such a co-location of EPO and HIF-1a 
expression suggested that the increased expression 
of EPO and HIF-1a could be associated with cells 
death in hypoxic perinecrotic fields. Undoubtedly, 
complete elucidation of the significance of extranuc-
lear accumulation of HIF-1a and its co-expression 
with EPO and EPOR in colorectal cancer requires 
further studies. 
The studies conducted in recent years have also 
demonstrated that EPO expression is not necessarily 
associated with the HIF-1a/b complex. It has been 
found that apart from hypoxia also other factors 
modulate the intensity of EPO production, including 
hypoglycemia, elevated intracellular concentration 
of calcium ions, increased levels of insulin, estrogens 
and androgens [28, 29]. Little is known about the role 
that EPOR may play in cancer cells. High expression 
of EPO/EPOR was found in preinvasive and invasive 
carcinoma of the breast, renal cancer, colorectal can-
cer, primary liver cancer and other tumors [8, 30–35]. 
Probably, the enhanced EPO binding to its receptor 
EPOR in cancer cells triggers JAK2 and then STAT5 
cascade [36]. However, it has to be noted that the 
studies of signal transduction pathways in cancer have 
been carried out mainly on cancer cell lines and their 
results do not always translate directly to the findings 
observed in vivo [36, 37]. It has been assumed that 
local paracrine action of erythropoietin activating 
the EPO/EPOR complex in cancer cells may promote 
tumor angiogenesis, especially in cancers characteri-
zed by the formation of a compact solid structure [33]. 
Despite a significant progress in our knowledge, 
the role of the EPO/EPOR complex in cancer cells 
still remains unclear, especially in association with 
other hypoxia-related proteins, such as HIF-1a [38]. 
Although our present findings confirm the existence 
of a strong correlation of HIF-1alpha expression with 
the expression of EPO and EPOR it seems likely that 
in a significant number of tumors, the expressions 
of EPO and EPOR may not be fully controlled by 
HIF-1a (in our CRC study values of correlation co-
efficients ranged from 0.5 to 0.6). The results seem 
to indicate complex biology of colorectal cancer and 
an important though not well known role of hypoxia 
and hypoxia-related proteins in the cancer progres-
sion. Further studies in this area of cancer biology 
are welcomed since the exogenous erythropoietin 
(rHuEpo) has been increasingly used in the treatment 
of cancer-associated anemia [39].
References
1. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol 
Pharmacol. 2006;70:1469–1480.
2. Lee JW, Bae SH, Jeong JW, Kim SH and Kim KW. Hy-
poxia-inducible factor (HIF-1) alpha: its protein stability and 
biological functions. Exp Mol Med. 2004;36:1–12.
3. Zagorska A, Dulak J. HIF-1: the knowns and unknowns of 
hypoxia sensing. Acta Biochim Pol. 2004;51:563–585.
4. D Bels D, Corazza F, Germonpré P and Balestra C. The 
normobaric oxygen paradox: A novel way to administer oxy-
gen as an adjuvant treatment for cancer? Med Hypotheses. 
2011;76:467–470.
5. Fisher JW. Erythropoietin: physiology and pharmacology 
update. Exp Biol Med. 2003;228:1–14.
325Hypoxia dependent markers and colorectal cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0043
www.fhc.viamedica.pl
6. Broxmeyer HE. Erythropoietin: multiple targets, actions, and 
modifying influences for biological and clinical consideration. 
J Exp Med. 2013;210:205–208.
7. Farrell F, Lee A. The erythropoietin receptor and its expres-
sion in tumor cells and other tissues. Oncologist. 2004;9:18–30.
8. Chabowska AM, Sulkowska M, Chabowski A, Wincewicz A, 
Koda M and Sulkowski S. Erythropoietin and erythropoietin 
receptor in colorectal cancer. Int J Surg Pathol. 2008;16:269–276.
9. Lee WY, Huang SC, Hsu KF, Tzeng CC, Shen WL. Roles 
for hypoxia-regulated genes during cervical carcinogenesis: 
somatic evolution during the hypoxia-glycolysis-acidosis 
sequence. Gynecol Oncol. 2008;108:377–384.
10. Lee AS, Kim DH, Lee JE et al. Erythropoietin induces lymph 
node lymphangiogenesis and lymph node tumor metastasis. 
Cancer Res. 2011;71:4506–4517.
11. Volgger B, Kurz K, Zöschg K et al. Importance of erythro-
poetin receptor expression in tumour tissue for the clinical 
course of breast cancer. Anticancer Res. 2010;30:3721–3726.
12. Wincewicz A, Sulkowska M, Koda M and Sulkowski S. Cli-
nicopathological significance and linkage of the distribution 
of HIF-1alpha and GLUT-1 in human primary colorectal 
cancer. Pathol Oncol Res. 2007;13:15–20.
13. Wincewicz A, Sulkowska M, Koda M, Leśniewicz T, Kanczu-
ga-Koda L and Sulkowski S. STAT3, HIF-1alpha, EPO and 
EPOR — signaling proteins in human primary ductal breast 
cancers. Folia Histochem Cytobiol. 2007;45:81–86.
14. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-in-
ducible factor 1 is a basic-helix-loop-helix-PAS heterodimer 
regulated by cellular O2 tension. Proc Natl Acad Sci USA. 
1995;92:5510–5514.
15. Wood SM, Wiesener MS, Yeates KM et al. Selection and 
analysis of a mutant cell line defective in the hypoxia-induci-
ble factor-1 alpha-subunit (HIF-1alpha). Characterization of 
HIF-1a-dependent and -independent hypoxia-inducible gene 
expression. J Biol Chem. 1998;273:8360–8368.
16. Yoshimura H, Dhar DK, Kohno H et al. Prognostic impact 
of hypoxia-inducible factors 1a and 2a in colorectal cancer 
patients: correlation with tumor angiogenesis and cyclooxy-
genase-2 expression. Clin Cancer Res. 2004;10:8554–8560.
17. Couvelard A, O’Toole D, Turley H et al. Microvascular 
density and hypoxia-inducible factor pathway in pancreatic 
endocrine tumours: negative correlation of microvascular 
density and VEGF expression with tumour progression. Br J 
Cancer. 2005;92:94–101.
18. Pansare V, Munkarah AR, Schimp V et al. Increased 
expression of hypoxia-inducible factor1a in type I and type 
II endometrial carcinomas. Modern Pathology. 2007;20:35–43.
19. Giatromanolaki A, Fiska A, Pitsiava D et al. Erythropoietin 
receptors in endometrial carcinoma as related to HIF1a and 
VEGF expression. In vivo. 2009;23:699–704.
20. Brown WM, Maxwell P, Graham AN et al. Erythropo-
ietin receptor expression in non-small cell lung carci-
noma: a question of antibody specificity. Stem Cells. 
2007;25:718–722.
21. Ribatti D, Marzullo A, Gentile A et al. Erythropoietin/
erythroproietin receptor system is involved in angiogene-
sis in human hepatocellular carcinoma. Histopathology. 
2007;50:591–596.
22. Ribatti D, Poliani PL, Longo V et al. Erythropoietin/ery-
throproietin receptor system is involved in angiogenesis in 
human neuroblastoma. Histopathology. 2007;50:636–641.
23. Kanczuga-Koda L, Sulkowska S, Koda M, Sulkowska M. 
Alterations in connexin 26 expression during colorectal car-
cinogenesis. Oncology. 2005;68:217–222.
24. Garofalo C, Koda M, Cascio S et al. Increased expression of 
leptin and the leptin receptor as a marker of breast cancer 
progression: possible role of obesity-related stimuli. Clin 
Cancer Res. 2006;12:1447–1453.
25. Brown LM, Cowen RL, Debray C et al. Reversing hypoxic 
cell chemoresistance in vitro using genetic and small mole-
cule approaches targeting hypoxia inducible factor-1. Mol 
Pharmacol. 2006;69:411–418.
26. Dagnon K, Pacary E, Commo F et al. Expression of erythro-
poietin and erythropoietin receptor in non-small cell lung 
carcinomas. Clin Cancer Res. 2005;11:993–999.
27. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance 
of erythropoietin expression in human endometrial carcino-
ma. Cancer. 2004;100:2376–2386.
28. Jelkmann W. Physiology and pharmacology of erythropoietin. 
Transfus Med Hemother. 2013;40:302–309.
29. Elliott S, Sinclair AM. The effect of erythropoietin on normal 
and neoplastic cells. Biologics. 2012;6:163–189.
30. Wincewicz A, Baltaziak M, Kanczuga-Koda L, Koda M, 
Sulkowska U, Sulkowski S. GLUT1 and Bcl-xL in relation 
to erythropoietin in human colorectal adenocarcinomas. 
Hepatogastroenterology. 2010;57:741–745.
31. Westenfelder C, Baranowski RL. Erythropoietin stimulates 
proliferation of human renal carcinoma cells. Kidney Int. 
2000;58:647–657.
32. Mohyeldin A, Lu H, Dalgard C et al. Erythropoietin signaling 
promotes invasiveness of human head and neck squamous 
cell carcinoma. Neoplasia. 2005;7:537–543.
33. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. 
Erythropoietin as an angiogenic factor in gastric carcinoma. 
Histopathology. 2003;42:246–250.
34. Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regula-
tes tumour growth of human malignancies. Carcinogenesis. 
2003;24:1021–1029.
35. Yin D, Kawabata H, Tcherniamtchouk O, Huynh T, Black 
KL, Koeffler HP. Glioblastoma multiforme cells: expression 
of erythropoietin receptor and response to erythropoietin. 
Int J Oncol. 2007;31:1193–1198.
36. Lai SY, Childs EE, Xi S et al. Erythropoietin-mediated ac-
tivation of JAK-STAT signaling contributes to cellular inva-
sion in head and neck squamous cell carcinoma. Oncogene. 
2005;24:4442–4449.
37. Wu XY, Fu ZX, Wang XH, Shen W. Identification of dif-
ferential proteins in colon cancer SW480 cells with HIF1a 
silence by proteome analysis. Neoplasma. 2010;57:299–305.
38. Gombos Z, Danihel L, Repiska V, Acs G, Furth E. Expres-
sion of erythropoietin and its receptor increases in colonic 
neoplastic progression: the role of hypoxia in tumorigenesis. 
Indian J Pathol Microbiol. 2011;54:273–278.
39. Wang L, Li HG, Xia ZS, Wen JM, Lv J. Prognostic signifi-
cance of erythropoietin and erythropoietin receptor in gastric 
adenocarcinoma. World J Gastroenterol. 2011;17:3933–3940.
Submitted: 11 November, 2013 
Accepted after reviews: 30 December, 2013
